> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs NeuroPharma Migraine Study
- URL: https://www.fdaweb.com/fda-oks-neuropharma-migraine-study/
- Published: 2018-06-22T12:00:00.000Z
- Updated: 2026-09-15T00:15:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141757

FDA has approved an Impel NeuroPharma IND for a Phase 3 clincial trial of INP104, a novel, dihydroergotamine (DHE) intranasal product for treating acute migraine. The drug is dosed via Impel’s proprietary Precision Olfactory Delivery. INP104 delivers DHE to the “richly vascularized upper nasal cavity, offering rapid bioavailability without injection,” the company says. The trial is expected to begin later this year.